HOSPIRA GLYCOPYRROLATE INJECTION glycopyrronium bromide (glycopyrrolate) 0.2 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

hospira glycopyrrolate injection glycopyrronium bromide (glycopyrrolate) 0.2 mg/1 ml solution for injection ampoule

pfizer australia pty ltd - glycopyrronium bromide (glycopyrrolate) -

GLYCOPYRRONIUM-AFT glycopyrronium bromide (glycopyrrolate) 200 microgram/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

glycopyrronium-aft glycopyrronium bromide (glycopyrrolate) 200 microgram/1 ml injection ampoule

aft pharmaceuticals pty ltd - glycopyrronium bromide, quantity: 200 microgram - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. ,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. ,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

ROBINUL glycopyrronium bromide (glycopyrrolate) 0.2mg/1mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

robinul glycopyrronium bromide (glycopyrrolate) 0.2mg/1ml injection ampoule

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - 1.as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2.as a preoperative or intraoperative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxa-methonium or due to cardiac vagal reflexes. 3.to protect against the peripheral muscarinic actions (eg. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by nondepolarising muscle relaxants.

Glycopyrronium bromide 2mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glycopyrronium bromide 2mg tablets

dawa ltd - glycopyrronium bromide - oral tablet - 2mg

Glycopyrronium bromide 1mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glycopyrronium bromide 1mg tablets

dawa ltd - glycopyrronium bromide - oral tablet - 1mg

ULTIBRO BREEZHALER 110/50 indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule Australia - English - Department of Health (Therapeutic Goods Administration)

ultibro breezhaler 110/50 indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); indacaterol maleate, quantity: 143 microgram (equivalent: indacaterol, qty 110 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - ultibro breezhaler 110/50 is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd), and for the reduction of exacerbations of copd in patients with a history of exacerbations.

SEEBRI BREEZHALER glycopyrronium (as bromide) 50 microgram powder for inhalation (in capsule) blister Australia - English - Department of Health (Therapeutic Goods Administration)

seebri breezhaler glycopyrronium (as bromide) 50 microgram powder for inhalation (in capsule) blister

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - inhalation, powder for - excipient ingredients: hypromellose; carrageenan; potassium chloride; magnesium stearate; purified water; sunset yellow fcf; lactose monohydrate; strong ammonia solution; ethanol absolute; propylene glycol; potassium hydroxide; butan-1-ol; shellac; iron oxide black; isopropyl alcohol - seebri breezhaler is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).

Glycopyrronium Bromide 200 micrograms/ml Solution for Injection New Zealand - English - Medsafe (Medicines Safety Authority)

glycopyrronium bromide 200 micrograms/ml solution for injection

max health limited - glycopyrronium bromide 0.2 mg/ml - solution for injection - 0.2 mg/ml - active: glycopyrronium bromide 0.2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - glycopyrrolate is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions: to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. glycopyrronium bromide 200 micrograms per ml solution for injection may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants. for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

DBL GLYCOPYRROLATE INJECTION glycopyrronium bromide (glycopyrrolate) 0.2 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dbl glycopyrrolate injection glycopyrronium bromide (glycopyrrolate) 0.2 mg/1 ml solution for injection ampoule

pfizer australia pty ltd - glycopyrronium bromide (glycopyrrolate) -

GLYCONEO 0.5/2.5 glycopyrronium bromide (glycopyrrolate) 0.5 mg/neostigmine methylsulfate 2.5 mg in 1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

glyconeo 0.5/2.5 glycopyrronium bromide (glycopyrrolate) 0.5 mg/neostigmine methylsulfate 2.5 mg in 1 ml solution for injection ampoule

ksj pharmatech - neostigmine methylsulfate, quantity: 2.5 mg; glycopyrronium bromide, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; citric acid; sodium hydroxide; dibasic sodium phosphate dodecahydrate - reversal of residual non-depolarising (competitive) neuromuscular block.